MIDATECH PHARMA
About Us | Management

The executive team and employees of Midatech represent a unique set of complementary competences, know-how and skill-sets in the life science industry. They have excellent senior executive track records in the global, pharmaceutical and biotech industry.

Dr Jim Phillips, MB, ChB, MBA
Chief Executive Officer

Dr Phillips has a strong background in company leadership and business development, and is a physician by training. He founded Talisker Pharma in 2004, which was the first and cornerstone acquisition of EUSA Pharma in 2006. As President of Europe and Senior Vice President, Corporate Development of EUSA Pharma Inc., Dr Phillips led the strategy resulting in the acquisition of OPI and its ultimate acquisition by Jazz Pharmaceuticals in 2012. Dr Phillips is currently a Non-executive Director of Herantis Pharma plc (listed in Helsinki) and Preci-Health SA (a private medical technology business).  He was formerly a Non-executive Director of Insense Ltd (a private spin-out from Unilever), and, until joining Midatech, was Chairman of Prosonix Limited, guiding its successful transformation into a respiratory focused business.

Dr Phillips initially held senior positions at Johnson & Johnson and Novartis Pharmaceuticals. At Novartis, he was in Clinical & Business Development and was a Board Director of the $1.3bn Arthritis, Bone, Gastrointestinal, Haematology and Infectious Diseases business unit and a member of the company’s Clinical Leadership Team.

Dr Jim Phillips has been awarded “Best CEO-Pharmaceuticals Industry” for 2015.

Nick Robbins-Cherry, ACA, MBA
Chief Financial Officer

Mr Robbins-Cherry is a Chartered Accountant and MBA with extensive commercial and finance experience gained in the life sciences, technology and consulting sectors, including roles at CACI Limited, Johnson & Johnson and ICI PLC. Mr Robbins-Cherry has a strong track record in mergers and acquisitions and of managing complex multi-national businesses. He qualified with Coopers & Lybrand (now PricewaterhouseCoopers) and has a BSc in Pharmacology.

Dr Craig Cook, MD, MBA
Chief Operating Officer / Chief Medical Officer
Chief Executive Officer Designate

Dr Cook has more than 15 years of international experience in the pharma, biomedical and high technology sectors including roles across a range of therapeutic areas, such as neurology, inflammatory, immunology, and endocrine, covering both drug development and medical affairs. He has established and led several healthcare initiatives, and held increasingly senior appointments at Johnson & Johnson, Eli Lilly, Novartis Pharma, and Serono Biotech. Dr Cook is lead adviser for Ippon Capital SA's life sciences practice.

He is a qualified physician, has a BSc in Pharmacology, Diploma in Anaesthesiology, and MBA from the London Business School. He joined Midatech in 2014 after leading and concluding the Ippon Capital investment round.

Dr Steve Damment, Ph.D.
Head of Research and Development

Dr Damment is an experienced leader in drug development with a 30-year track record of advancing drug candidates through key development milestones to successful product registration. He has extensive experience identifying high-value drug candidates; crafting drug development programmes for optimal regulatory and commercial positioning; overseeing complex research programs; creating high quality regulatory documentation and defending safety and efficacy positions with regulatory agencies in the US, Europe and Japan.  He is well networked with the investment community, opinion leaders and specialist drug development scientists in the pharma industry, contract research, professional societies and academia.

He has held a number of senior pharmaceutical research and development positions including roles with Glaxo-Wellcome (now GSK) and Shire Pharmaceuticals where he was Senior Vice President of Biosciences.  He joined Midatech in 2015 as Head of Translational Medicine.”

Rob Rainey, FCA MBA MA
Head of Corporate Development

Rob worked for SmithKline Beecham and then GSK for 11 years in  a variety of roles in finance, operations, business development and country management and during that time was based in Russia and Spain for a number of years, as well as London. Rob was subsequently Finance Director for Talisker Pharma, which was then acquired by EUSA pharma.  Most recently he worked in emerging markets private equity for 8 years at Ashmore Group. Rob is a Chartered Accountant, has an MBA from London Business School and an MA in Natural Sciences.

David Benharris
President, Midatech Pharma US, Inc.

Mr. Benharris has a strong background in all aspects of commercial operations and business development in both the biotech and specialty pharma sectors. He is Former Senior Vice President, Commercial Operations & Business Development at Midatech Pharma US (ex DARA Biosciences, Inc.).

Mr. Benharris was the Co- founder of Oncogenerix, which was acquired by DARA BioSciences and he also was the VP of Strategic Partnerships & VP of Sales and Marketing of Savient Pharmaceuticals (NASDAQ:SVNT): instrumental in the successful launch and commercial development of Oxandrin.

David held various commercial management positions in the industry: he was a Sales Director at EMD Serono, National Sales Director of Insmed Incorporated (Nasdaq:INSM), President of DBI Consulting, working on the product launches of Mozibil (Genzyme), Kuvan (BioMarin), and Zanaflex (Accorda).

David has a BS Degree in Marketing and Management from Northeastern University.

About Us
Management

The executive team and employees of Midatech represent a unique set of complementary competences, know-how and skill-sets in the life science industry. They have excellent senior executive track records in the global, pharmaceutical and biotech industry.

Dr Jim Phillips, MB, ChB, MBA
Chief Executive Officer

Dr Phillips has a strong background in company leadership and business development, and is a physician by training. He founded Talisker Pharma in 2004, which was the first and cornerstone acquisition of EUSA Pharma in 2006. As President of Europe and Senior Vice President, Corporate Development of EUSA Pharma Inc., Dr Phillips led the strategy resulting in the acquisition of OPI and its ultimate acquisition by Jazz Pharmaceuticals in 2012. Dr Phillips is currently a Non-executive Director of Herantis Pharma plc (listed in Helsinki) and Preci-Health SA (a private medical technology business).  He was formerly a Non-executive Director of Insense Ltd (a private spin-out from Unilever), and, until joining Midatech, was Chairman of Prosonix Limited, guiding its successful transformation into a respiratory focused business.

Dr Phillips initially held senior positions at Johnson & Johnson and Novartis Pharmaceuticals. At Novartis, he was in Clinical & Business Development and was a Board Director of the $1.3bn Arthritis, Bone, Gastrointestinal, Haematology and Infectious Diseases business unit and a member of the company’s Clinical Leadership Team.

Dr Jim Phillips has been awarded “Best CEO-Pharmaceuticals Industry” for 2015.

Nick Robbins-Cherry, ACA, MBA
Chief Financial Officer

Mr Robbins-Cherry is a Chartered Accountant and MBA with extensive commercial and finance experience gained in the life sciences, technology and consulting sectors, including roles at CACI Limited, Johnson & Johnson and ICI PLC. Mr Robbins-Cherry has a strong track record in mergers and acquisitions and of managing complex multi-national businesses. He qualified with Coopers & Lybrand (now PricewaterhouseCoopers) and has a BSc in Pharmacology.

Dr Craig Cook, MD, MBA
Chief Operating Officer / Chief Medical Officer
Chief Executive Officer Designate

Dr Cook has more than 15 years of international experience in the pharma, biomedical and high technology sectors including roles across a range of therapeutic areas, such as neurology, inflammatory, immunology, and endocrine, covering both drug development and medical affairs. He has established and led several healthcare initiatives, and held increasingly senior appointments at Johnson & Johnson, Eli Lilly, Novartis Pharma, and Serono Biotech. Dr Cook is lead adviser for Ippon Capital SA's life sciences practice.

He is a qualified physician, has a BSc in Pharmacology, Diploma in Anaesthesiology, and MBA from the London Business School. He joined Midatech in 2014 after leading and concluding the Ippon Capital investment round.

Dr Steve Damment, Ph.D.
Head of Research and Development

Dr Damment is an experienced leader in drug development with a 30-year track record of advancing drug candidates through key development milestones to successful product registration. He has extensive experience identifying high-value drug candidates; crafting drug development programmes for optimal regulatory and commercial positioning; overseeing complex research programs; creating high quality regulatory documentation and defending safety and efficacy positions with regulatory agencies in the US, Europe and Japan.  He is well networked with the investment community, opinion leaders and specialist drug development scientists in the pharma industry, contract research, professional societies and academia.

He has held a number of senior pharmaceutical research and development positions including roles with Glaxo-Wellcome (now GSK) and Shire Pharmaceuticals where he was Senior Vice President of Biosciences.  He joined Midatech in 2015 as Head of Translational Medicine.”

Rob Rainey, FCA MBA MA
Head of Corporate Development

Rob worked for SmithKline Beecham and then GSK for 11 years in  a variety of roles in finance, operations, business development and country management and during that time was based in Russia and Spain for a number of years, as well as London. Rob was subsequently Finance Director for Talisker Pharma, which was then acquired by EUSA pharma.  Most recently he worked in emerging markets private equity for 8 years at Ashmore Group. Rob is a Chartered Accountant, has an MBA from London Business School and an MA in Natural Sciences.

David Benharris
President, Midatech Pharma US, Inc.

Mr. Benharris has a strong background in all aspects of commercial operations and business development in both the biotech and specialty pharma sectors. He is Former Senior Vice President, Commercial Operations & Business Development at Midatech Pharma US (ex DARA Biosciences, Inc.).

Mr. Benharris was the Co- founder of Oncogenerix, which was acquired by DARA BioSciences and he also was the VP of Strategic Partnerships & VP of Sales and Marketing of Savient Pharmaceuticals (NASDAQ:SVNT): instrumental in the successful launch and commercial development of Oxandrin.

David held various commercial management positions in the industry: he was a Sales Director at EMD Serono, National Sales Director of Insmed Incorporated (Nasdaq:INSM), President of DBI Consulting, working on the product launches of Mozibil (Genzyme), Kuvan (BioMarin), and Zanaflex (Accorda).

David has a BS Degree in Marketing and Management from Northeastern University.

© Copyright 2018 Midatech Pharma PLC